Skip to main content
. 2016 Jul 18;2:18. doi: 10.1186/s40942-016-0042-y

Table 2.

Baseline characteristics of each group

Early Obvious Severe
Age (years) 63 (57–74) 65 (48–75) 74 (63–76)
Cumulative dose (g) 730 (438–949) 1933 (584–4380) 1030 (890–1679)
Baseline vision 20/20–20/40 20/20–20/60 20/100–20/400
Follow-up (months) 13 (12–56) 36 (12–56) 14 (13–36)

Median (range) reported for age, cumulative dose, and follow-up